acamprosate vs atomoxetine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and atomoxetine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Strattera
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Atomoxetine (Strattera) is a medicine that can help people with Attention-Deficit/Hyperactivity Disorder (ADHD). It works by affecting a chemical in the brain called norepinephrine.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Atomoxetine is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD can cause you to be hyperactive, impulsive, and have trouble paying attention. This medicine can help you focus, be less impulsive, and feel calmer. It is for both kids and adults.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Atomoxetine works by increasing the amount of norepinephrine in your brain. Norepinephrine is a chemical that helps you pay attention and control your impulses. By increasing norepinephrine, atomoxetine can improve ADHD symptoms.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Feeling sick to your stomach
- • Throwing up
- • Feeling tired
- • Not feeling hungry
- • Belly pain
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Nausea 431
- Headache 407
- Fatigue 401
- Condition Aggravated 395
- Hypertension 388
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Atomoxetine can increase the risk of suicidal thoughts in children and teenagers. Watch carefully for worsening mood or any unusual changes in behavior. Tell your doctor right away if you have any suicidal thoughts or feelings.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if atomoxetine will harm your unborn baby. There is a pregnancy registry for women who take ADHD medicines during pregnancy. Talk to your doctor about how to register.
How to Read This acamprosate vs atomoxetine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while atomoxetine sits within the Selective Norepinephrine Reuptake Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while atomoxetine has 2,022. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or atomoxetine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.